When CD24 targeted siRNA molecules are added to the growth medium of several epithelial cancer cell lines, such as breast cancer and prostate cancer, the transient low expression of CD24 leads to the decrease of cell growth, and the changes of actin cytoskeleton can be observed, which results in exercise damage (18). The gene discussed is CD24; the disease is prostate carcinoma.